Navigation Links
Novagali Pharma Presents at AACO the Results of its Pivotal Phase,III Clinical Trial of Vekacia in Children Suffering From Vernal,Keratoconjunctivitis

five patients had detectable CsA levels below 0.33ng/ml, a value which is considered as negligible

These results are presented at the occasion of a Symposium chaired by Pr BenEzra, lead coordinator of the study.

About Novagali Pharma Vekacia(R):

Vekacia(R) is a Cyclosporine A ophthalmic product intended for patients suffering from vernal keratoconjunctivitis. Vekacia(R) is a proprietary cationic emulsion enabling an efficient and unmatched-level drug absorption in tissues of the eye leading to optimal therapeutic efficacy.

About Novagali Pharma: www.novagali.com

Novagali Pharma SA is an emerging ophthalmic pharmaceutical company based in the Genopole biocluster in Evry, France, that develops innovative products for all segments of the eye. Thanks to its proprietary technology platforms Novasorb(R) and Eyeject(R), the company has developed a broad pipeline of innovative products addressing main ocular conditions as well as orphan diseases. Most advanced products include Vekacia(R), an orphan product for treatment of vernal keratoconjunctivitis; Cationorm(R), a CE marking product for dry eye relief; and Nova22007, a product for the treatment of moderate-to-severe dry eye syndrome. Founded in 2000, the firm has raised a total amount of Euro 44 million in 3 series of financing and currently has 38 employees.

    Contacts Presse

    Novagali

    VP HR & Communication

    Genevieve Garrigos

    +33-1-69-87-40-20

    


    Euro RSCG

    Estelle Griffe

    +33-1-58-47-95-25 / +33-6-23-75-09-23

    



genevieve.garrigos@novagali.com Estelle.griffe@eurorscg.fr

Nova Gali Pharma

CONTACT: Contacts Presse: Novagali, VP HR & Communication, GenevieveGarrigos, +33-1-69-87-40-20, ; Euro RSCG,Estelle Griffe, +33-1-58-4
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Novagali Pharma Announces Positive Vekacia Clinical Results From Pivotal Phase III Trial in Vernal Keratoconjunctivitis
2. Sygnis Pharma AG announces date for presentation of clinical results
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
7. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
8. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
9. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Array BioPharma to Present at the C.E Unterbeg, Towbin Emerging Growth Conference
11. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
Post Your Comments:
(Date:8/28/2014)... Colo. , Aug. 28, 2014   Venaxis, ... company focused on obtaining FDA clearance for and commercializing ... blood test for aiding in identifying children, adolescent, and ... at low risk for appendicitis, today announced it will ... Renshaw 16 th Annual Global Investment Conference being ...
(Date:8/28/2014)... 2014  Robotic surgery is creating buzz among ... the promise of improved outcomes and the potential ... surgical robots and market pressures to use this ... their robotic surgery training programs and ensure proper ... ECRI Institute ( www.ecri.org ), a nonprofit ...
(Date:8/28/2014)... , Aug. 28, 2014  Critical Process ... , today announces the expansion of their ... Critical Process Filtration now offers customers and potential ... fluids to filter failure analyses (even for competitor ... to their hallmark services of system benchmarking and ...
Breaking Medicine Technology:Venaxis to Present at September Investor Conferences 2Venaxis to Present at September Investor Conferences 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 2Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 3Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 4Surgical Robot Risk and Safety: ECRI Institute and Hartford Hospital Launch New Education Series 5Critical Process Filtration, Inc. Announces Expanded Technical Services and Validation Support 2
(Date:8/28/2014)... of women who are given information about the chance ... not fully understand the risks involved, according to research ... , today (Friday). , In a survey of around ... London (UCL) found that 64 per cent felt they ... chance that screening will pick up cancers that would ...
(Date:8/28/2014)... 28, 2014 Millennium Treatment Group ... September. This month will be a celebration of ... health services. Along with other treatment facilities and ... to spread the word about this national observance. ... the work of treatment and recovery professionals, and ...
(Date:8/28/2014)... August 28, 2014 Millennium Treatment Group ... users in the workplace. A recent report from ... states that drug abuse is costing employers an ... or are addicted to drugs affect their employers and ... over into the workplace, causing expensive problems for their ...
(Date:8/28/2014)... Reinberg HealthDay Reporter THURSDAY, ... the diet may worsen symptoms of multiple sclerosis (MS), a ... MS, such as vitamin D, smoking and Epstein Barr virus ... another environmental factor affecting MS patients," said lead researcher Dr. ... in Buenos Aires. Multiple sclerosis is a disease of ...
(Date:8/28/2014)... 28, 2014 Testimony began this ... a transvaginal mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ )involving ... LLP reports. Court documents pending in the U.S. ... that the case was filed on behalf of ... surgeries, allegedly due to vaginal mesh complications associated ...
Breaking Medicine News(10 mins):Health News:Some women still don't underststand 'overdiagnosis' risk in breast screening 2Health News:Millennium Treatment Group Celebrates National Recovery Month 2Health News:Drug Use Causes Problems in the Workplace 2Health News:Could Too Much Salt Harm MS Patients? 2Health News:Could Too Much Salt Harm MS Patients? 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit News: Testimony Begins in Second Federal Ethicon Bellwether Trial, Bernstein Liebhard LLP Reports 4
... risk when taking nortriptyline than escitalopram, study finds , ... the antidepressant nortriptyline (Aventyl) are nearly 10 times more ... the antidepressant escitalopram (Lexapro, Cipralex), a new study has ... BMC Medicine , included 811 people with ...
... 13 , News facts: , ... community for individuals with breast cancer, however the experiences of ... stage of the disease, is rarely discussed., MBC, also ... occurs when cancer has spread beyond the breast to other ...
... Md., Oct. 15 The U.S. Food and Drug ... purchasing any products over the Internet that claim to ... The warning comes after the FDA recently purchased and ... may pose risks to patients. , (Logo: ...
... Oct. 15 Mayo Clinic clinicians and designers, along ... a tool to involve patients more in their diabetes ... decision aid cards, could help patients make decisions involving ... results of this randomized trial are in September,s issue ...
... With national focus on health reform, NY hospital system looks to ... area,s largest automated medical record system , GREAT NECK, ... it is subsidizing up to 85 percent of the cost of ... offices of its more than 7,000 affiliated physicians in New York ...
... will host "S,more to Love", a cocktail fundraiser on Friday, November ... benefit Birch Family Camp. , Celebrating its 20th year, the Birch ... the 5 boroughs of NYC, along with 200 volunteers for a ... located in the Hudson Valley. Throughout the year this community ...
Cached Medicine News:Health News:Video: Cities and States Around the U.S. Recognize October 13 as Metastatic Breast Cancer Awareness Day 2Health News:Video: Cities and States Around the U.S. Recognize October 13 as Metastatic Breast Cancer Awareness Day 3Health News:FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 2Health News:FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 3Health News:Mayo Clinic Clinicians Develop New Decision Aid Tool to Help Type 2 Diabetes Patients 2Health News:Mayo Clinic Clinicians Develop New Decision Aid Tool to Help Type 2 Diabetes Patients 3Health News:Mayo Clinic Clinicians Develop New Decision Aid Tool to Help Type 2 Diabetes Patients 4Health News:North Shore-LIJ Health System Investing $400M to Connect Up to 7,000 Physicians, 13 Hospitals with Electronic Health Records System 2Health News:North Shore-LIJ Health System Investing $400M to Connect Up to 7,000 Physicians, 13 Hospitals with Electronic Health Records System 3Health News:North Shore-LIJ Health System Investing $400M to Connect Up to 7,000 Physicians, 13 Hospitals with Electronic Health Records System 4Health News:North Shore-LIJ Health System Investing $400M to Connect Up to 7,000 Physicians, 13 Hospitals with Electronic Health Records System 5Health News:North Shore-LIJ Health System Investing $400M to Connect Up to 7,000 Physicians, 13 Hospitals with Electronic Health Records System 6Health News:North Shore-LIJ Health System Investing $400M to Connect Up to 7,000 Physicians, 13 Hospitals with Electronic Health Records System 7Health News:One Heartland Hosting: S'more to Love Cocktail Fundraiser 2
... specifically for detection of recent-onset neovascular ("wet") ... maps and quantifies visual field defects consistent ... to the wet stage of the disease. ... for small visual field defects, the PreView ...
... a new functional test which exhibits 100% ... C Resistance caused by the Factor V ... commercially available methods, Pefakit APC-R FVL shows ... Lupus Anticoagulants, Elevated FVIII levels, Heparins or ...
Cable connections for 5 different adapters: Storz, ACMI, Pentax, Wolf and Olympus....
Lightweight PVC housing for easy transport, integrated handle. Easy lamp exchange....
Medicine Products: